The Food and Drug Administration (FDA) told the maker of Purell to discontinue marketing campaigns that includes claims for avoiding flu and ebola, according to an article on The New York Times website.
The campaigns also claim the product can prevent spread of MRSA and norovirus.
The FDA told Gojo Industries that its claims that Purell could reduce the potential for infection or prevent illnesses violated the Federal Food, Drug and Cosmetic Act.
The agency said it was reclassifying Purell as an unapproved drug, rather than an over-the-counter product.
Why Cyber Readiness Is the New Standard of Care
Smarter, Faster, Safer: The Rise of AI in Healthcare Security Technologies
The WHO and UNICEF Release New Global Hand Hygiene Guidelines
Swatting Calls, Hoax Threats Have Real Consequences for Healthcare
Next Level Announces Expansion of Conroe, Texas Clinic